newsfilter
← Latest News
GlobeNewswire·

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

ACHFFSPRO
  • Avacta Therapeutics appointed Dr. Patrick Vink as Non-Executive Deputy Chairman & Senior Independent Director on July 08, 2026.
  • Dr. Vink currently serves as Chairman at Arch Biopartners Inc. & on the board of Spero Therapeutics Inc. as Nominating & Corporate Governance Chair.
  • He is Chairman of Micreos Group, Secura Bio Inc., & F2G Ltd, & acts as a senior advisor to Athyrium Capital Management LP & Forbion Ventures.
  • CEO Christina Coughlin stated Dr. Vink brings extensive experience in Pharma partnering, financing, & operations to support Avacta's pipeline advancement.
  • Dr. Vink highlighted the potential of the pre|CISION® platform & upcoming clinical data for the Gen Two product AVA6103.
  • Previously, Dr. Vink was Executive Vice-President & Chief Operating Officer at Cubist Pharmaceuticals until its acquisition by Merck.
  • His career includes senior roles at Sanofi, Biogen, Sandoz, & Mylan, & he served on the EFPIA Executive Committee between 2013 & 2015.
  • Dr. Vink graduated as a medical doctor from the University of Leiden in 1988 & earned an MBA from the University of Rochester in 1992.
  • Avacta's pre|CISION® platform uses a tumor-specific protease (FAP) to concentrate potent payloads in the tumor microenvironment while sparing normal tissues.
  • The lead clinical program faridoxorubicin (AVA6000) is a Gen One version of doxorubicin showing preliminary activity in salivary gland cancer & soft tissue sarcoma.
  • AVA6103 is a Gen Two candidate utilizing a sustained release mechanism evaluated in the FOCUS-01 Phase 1 trial to minimize systemic exposure.
  • Dr. Vink holds no ordinary shares in Avacta & disclosed no further information required under AIM Rule 17 or Schedule 2(g).